UNASSIGNED: The aim of this study was to evaluate the effect of arsenic trioxide as a single agent in @entity2799 cases for induction, consolidation, and maintenance therapy in a long-term, 11-year follow-up. We studied 60 @entity1 with @entity2799 . Sixty percent of the @entity1 were aged between 12 and 24   years. Arsenic trioxide was infused at a 0.15   mg/kg daily dose until complete remission was achieved. After 2   weeks of rest, arsenic trioxide was infused daily for 28   days as a consolidation therapy. Then, arsenic infusions were given every 3-4   months for 14   days for 2   years, and the @entity1 were followed until relapse or @entity204 . The rates of complete remission, disease-free survival, overall survival, and @entity137 were evaluated. The morphologic complete remission was observed in 55 out of the 60 @entity1 . The most common causes of a remission failure were early mortality because of the @entity2799 and the lack of response to arsenic treatment. The mean follow-up was 90   months. The primary outcomes for males and females were a mean disease-free survival of 101 and 97   months, respectively, and a mean overall survival of 103 and 101   months, respectively. From the 55 cases with remission, three @entity1 died (late mortality). Of the 60 @entity1 , 85% are still alive. Arsenic trioxide was generally well tolerated. The long-term follow-up of @entity1 with @entity2799 , treated with arsenic alone as induction, consolidation, and maintenance therapy, shows high cure rates and excellent outcomes. Copyright    2015 John Wiley _ Sons, Ltd.

Induction, consolidation, and maintenance therapies with arsenic as a single agent for XXXX in a 11-year follow-up.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2799 :: ('MESH:D015473', 'Disease') :: ['APL', 'APL differentiation syndrome', 'acute promyelocytic leukaemia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity137 :: ('MESH:D064420', 'Disease') :: ['drug toxicity']
@entity2799 :: (MESH:D015473,Disease) :: ['acute promyelocytic leukaemia']
